
Opinion|Videos|March 28, 2025
Balancing Approved Therapies and Patient Preference in Parkinson Disease
Author(s)Daniel E. Kremens, MD, JD
An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.
Advertisement
Episodes in this series

Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia
2
Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease
3
Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient
4
Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival
5



























